PIK3CA and head and neck squamous cell carcinoma: A recent study in head and neck squamous cell carcinomas highlighted that genomic aberrations including EGFR amplifications, AKT1 amplifications and CSMD1 deletions, but not PIK3CA, were highly associated with responsiveness to PI3K-targeted drugs [44].